FDA update for supplemental NDA for Hetlioz (tasimelteon) in the treatment of insomnia – Vanda Pharma
Vanda Pharmaceuticals Inc. announced that on February 4, 2024, it received a notification from the FDA stating that as part of its ongoing review of Vanda’s supplemental New… read more.